NCT01207921View on ClinicalTrials.gov

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 28, 2011

Primary Completion Date

September 19, 2016

Study Completion Date

March 5, 2021

Conditions
Hodgkin Disease
Interventions
DRUG

Lenalidomide

Trial Locations (3)

27106

Wake Forest University, Winston-Salem

43210

Ohio State University, Columbus

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Washington University School of Medicine

OTHER